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Abstract
Background: Invasive fungal disease (IFD) is a frequent and serious infectious complication in
immunocompromised patients. Culture and cytology in bronchoalveolar lavage (BAL) have a high specificity but
low sensitivity for the diagnosis of IFD as assessed by histology. Molecular methods are expected to allow a rapid
diagnosis of IFD with a high sensitivity. We evaluated the diagnostic accuracy of conventional nested PCR in the
bronchoalveolar fluid to diagnose IFD in severely immunocompromised patients.
Methods: Consecutive immunosuppressed patients undergoing bronchoscopy for suspected pulmonary infection
in a tertiary care hospital were included. Patients were classified as having “proven”, “probable”, “possible”, and “no”
IFD based on definitions of the European Organization for Research and Treatment of Cancer and National Institute
of Allergy and Infectious Diseases (EORTC/NIAID) and on clinical grounds. Conventional nested PCR for aspergillus
fumigatus, flavus, niger, glaucus, terreus and tomarrii were applied to 2.5 ml bronchoalveolar fluid.
Results: A total of 191 patients were included. Mean age was 51 y, 61% were male. There were 129 patients with
hematological conditions, 26 solid organ transplant recipients, 24 auto-immune disorders, and 12 HIV. According to
the EORTC/NIAID classification, there were 53 patients with potential IFD: 3 (2%) had proven, 8 (4%) probable,
42 (22%) possible and 138 (72%) no IFD. A total of 111 (58%) of the patients - 10 (90.9%) proven or probable IFD,
32 (76.2%) possible IFD and 69 (50%) “no” IFD) were on anti-fungal therapy at the time of bronchoscopy.
Conventional nested PCR for Aspergillus was positive in 55 cases (28.8%). According to these results, sensitivity,
specificity, PPV and NPV for “proven” IFD was 0%, 71%, 0%, 98%, respectively and “probable” IFD was 36%, 72%, 7%,
95%, respectively. In 53 (28%) cases there was a strong clinical suspicion of IFD in the chest-x-ray and/or chest-CT
irrespective of the EORTC/NIAID classification. However, from those, only 15 (28%) had a positive conventional
nested PCR.
Conclusion: In our experience, conventional nested Aspergillus PCR in the BAL seems to be of limited usefulness
for detection of invasive fungal disease in immunocompromised patients due to the limited sensitivity and
specificity of the method.
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Background
Invasive fungal disease (IFD) is a frequent and serious in-
fectious complication in immunocompromised patients.
Despite the introduction of voriconazole and other new
antifungal agents the mortality remains as high as 30%
[1]. For instance, the treatment of invasive aspergillosis
with intravenous antifungal therapy produced median
hospital costs of $52 803 between 2000 and 2006 in the
US, although the mortality stayed up to 36.7% [2].
Typical features of IFD on CT scan include the halo
sign or cavities. However, in many cases, there are only
unspecific infiltrates. Culture and cytology in BAL have
a high specificity (70–95%) but low sensitivity (0–88%)
for the diagnosis of IFD in neutropenic patients as
assessed by histology [3]. Serum galactomannan has
been suggested as a non-invasive marker for the diagno-
sis of IFD in neutropenic patients [4,5]. Conversely, a
number of studies showed prominent false positive
results [6,7]. The reported sensitivity of serum galacto-
mannan ranges from 50 to 73% [8-10]. Herein, bronch-
oalveolar lavage galactomannan probably has a higher
sensitivity than serum galactomannan [9]. Nevertheless,
the specificity of serum galactomannan was 98% or
higher in most collectives studied [11].
Currently, the gold-standard for diagnosis of invasive
pulmonary aspergillosis remains the direct examination
or culture of pulmonary tissue obtained by transbron-
chial or open lung biopsy [12]. Unfortunately, these pro-
cedures might be associated with considerable morbidity
and mortality in this particular patient population. While
transbronchial biopsies are considered safe in non-
immunosuppressed patients with a normal coagulation
systems [13,14] decreases in the platelet function or
number are linked to a considerable increase in peri-
interventional parenchymal bleeding [15]. Surgical biopsy
reliably allows detecting pulmonary IFD in a diagnostic
and therapeutic approach [16,17]. However, both proce-
dures require specialized, experienced physicians and
institutions. Therefore, the development of a reliable,
sensitive method to confirm the presence of invasive pul-
monary aspergillosis would represent a desirable advance
for the adequate treatment of patients at risk [12].
Molecular diagnostic methods for detection of fungal
infection have been described in the immunosuppressed
population. Khot et al. reported sensitivity, specificity,
positive and negative predictive values of 77%, 88%, 50%,
96%, respectively, for a quantitative PCR in the bronch-
oalveolar lavage (BAL) of 81 patients with hematological
malignancies or undergoing hematopoietic cell trans-
plantation [18]. Tuon et al. reviewed 15 studies using
PCR in BAL samples to detect invasive aspergillosis and
described overall an sensitivity and specificity values of
PCR-based techniques to be 79% and 94%, respectivel
[19]. Although major concerns related to the lack of
external standardization, wide plethora of different
methods (real-time, nested, etc.) and need for larger
studies have been widely acknowledged, [19] the mo-
lecular diagnostic in the BAL seems to be a promising
approach for the diagnosis of IFD. Hence, harmonization
efforts are ongoing in order to help integrating PCR into
the next revision of the EORTC classification [20].
In this study, we aimed to evaluate the diagnostic
value of conventional nested PCR to detect aspergillus
fumigatus, flavus, niger, glaucus, terreus and tomarrii in
the bronchoalveolar fluids in a well-characterized, large
population of immunosuppressed patients.
Methods
This is a prospective, investigator-initiated and –driven,
observational, monocentric cohort study. Data of 191
immunocompromised patients undergoing flexible bron-
choscopy over a two year period at the Clinic for Pul-
monary Medicine, University Hospital Basel, a 784-bed
tertiary care hospital located in Basel, Switzerland were
analyzed. The primary goal of the study was to evaluate
the diagnostic performance of conventional nested PCR
to detect aspergillus fumigatus, flavus, niger, glaucus,
terreus and tomarrii in the bronchoalveolar fluids for the
diagnosis of invasive fungal disease in immunosup-
pressed patients.
Inclusion criteria were: a) age ≥ 18, b) immunocom-
promised state as defined by hematologic or other ma-
lignancy treated by high-dose chemotherapy and/or
stem cell transplantation; solid organ transplantation;
AIDS; long-term corticosteroid therapy (i.e., > = 20 mg/d
prednisone equivalent for > = 2 months), current use of
immunosuppressive, or cytotoxic medication for indica-
tions other than organ or stem cell transplantation;
c) decision by the pulmonary consultant to perform
bronchoscopy due to suspected pulmonary infection;
d) informed consent by the patient to undergo flexible
bronchoscopy and related data analysis. Exclusion cri-
teria were pregnancy and inability to provide informed
consent. The study was approved by the Basel Ethics
Committee. All patients gave written informed consent.
Definitions
Suspected pulmonary infection was defined by the pres-
ence of respiratory symptoms, fever and/or new or pro-
gressive radiology findings, as judged by the attending
physician.
Flexible bronchoscopy was performed with the patient
under conscious sedation using hydrocodone and mida-
zolam according to the British Thoracic Society guide-
lines [21]. BAL was performed by the three installations
of 50 mL each of a pyrogen-free, sterile, 0.9% NaCL so-
lution over the working channel of the bronchoscope
according to standard guidelines [22]. In patients with
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no or diffuse pulmonary infiltrates, BAL was performed
either in the right middle lobe or the lingula. For patients
with focal lung infiltrates, BAL was performed in the
pulmonary segment corresponding to the radiologic
abnormality. BAL fluid was recovered by suction. Besides
BAL, the choice of further sampling techniques used
during bronchoscopy, such as endo- or transbronchial
biopsies or transbronchial needle aspiration, was at the
pulmonologist’s discretion.
The microbiological diagnostic workup included a
search for Legionella pneumophila, Chlamydia pneumo-
niae, Mycoplasma pneumoniae, and respiratory viruses
(i.e., herpes simplex virus, cytomegalovirus, respiratory
syncytial virus, and adenovirus) by polymerase chain
reaction, culture, or immunofluorescence. Appropriate
stains and cultures for bacteria, mycobacteria, fungi, and
Pneumocystis jiroveci were performed. Positive bacterial
cultures were counted as the number of colony-forming
units per milliliter, and identification and susceptibility
tests were performed according to standard methods.
Histologic lung biopsy specimens, recovered by trans-
bronchial biopsy, endobronchial biopsy, video assisted
thoracic surgery, and autopsy, were obtained according
to the clinical setting. Cytologic analysis of BAL fluid was
performed with hematoxylin-eosin staining. Cell differen-
tiation in BAL fluid was reported as absolute numbers
and as a percentage of the total cell count [22].
Severe neutropenia was defined as an absolute neutro-
phil count of < 0.5 x 10 9 cells/L.
Patients were examined, treated, and followed up
according to the usual practice of the institution. Par-
ticularly, the decision to obtain tissue for histological
examination was left at the discretion of the attending
physician. Chest radiographs were performed in most
cases, and CT scans were obtained, as indicated by the
treating physicians, in 143 (74.9%) patients. Clinical
diagnoses were determined from physician notes, hos-
pital discharge summaries, laboratory studies, radiologic
examinations, and pathologic reports.
Invasive pulmonary aspergillosis was defined by the
cytologic or histopathologic demonstration of the pres-
ence of Aspergillus or the isolation of Aspergillus in a
respiratory specimen in the presence of a compatible
clinical and radiographic pattern according to a consen-
sus statement of the Invasive Fungal Infections Coopera-
tive Group, European Organization for Research and
Treatment of Cancer, and Mycosis Study Group of the
National Institute of Allergy and Infectious Disease [23].
Aspergillus conventional nested PCR
Conventional nested PCR to detect aspergillus fumiga-
tus, flavus, niger, glaucus, terreus and tomarrii was
performed in 2.5 ml leftovers of bronchoalveolar fluid.
BAL material was centrifuged and DNA extracted from
the pellet using EZ1 DNA Tissue Kit (QIAGEN AG,
Hombrechtikon, Switzerland) as described by the manufac-
turer. The presence of adequate DNA was confirmed by
amplifying the human beta-globin gene as previously
described [24]. Previously described specific sequences of
5.8 sRNA and 18 sRNA of Aspergillus sp. were chosen as
target sequences with slight modification [25]. The following
primers were used for the detection of Aspergillus
DNA: AspNest1 (5’-TCTTGGTTCCGGCATCGAT-3) and
AspNest2 (5’TGACAAAGCCCCATACGCT-3’) for the first
round and AspNest3 (5’-GAAGAACGCAGCGAAATGC-3’)
and AspNest4 (5’-AACACACAAGCCGTGCTTGA-3’)
for the second round, respectively, leading to a final PCR
product of 146 bp. The basic amplification reactions were
done using a volume of 50 μl containing 100 to 500 ng of
DNA, 2.5 ml of each primer (final concentration 3 mM),
25 μl Master Mix Gold (Applied Biosystems, Paris,
France) [26]. Amplification and detection were performed
on the ABI 9800 Fast Thermal Cycler (Applied Biosys-
tem) using for both primer sets, the same cycling condi-
tions with an initial cycling step at 94°C for 10 minutes
followed by 94°C, 55°C and 72°C for 30 seconds each
ending at 4°C. Ten microliters of each amplification prod-
uct were analyzed by electrophoresis in an ethidium
bromide-containing 2% agarose gel. In addition, PCR pro-
ducts were extracted from a low melting agarose gel and
DNA sequencing was performed to confirm the appropri-
ate DNA sequence. Stringent laboratory conditions and
appropriate negative and positive controls were per-
formed in each run.
Statistical analysis
Differences in dichotomous variables were evaluated
using the Chi-square test or Fischer’s exact test, as
appropriate. Normally distributed parameters were ana-
lyzed using the Student’s t-test for equality of means. All
other continuously non-normally distributed parameters
were evaluated using the non-parametric Mann–Whitney
U test or Kruskal-Wallis test, as appropriate.
The Statistical Package for Social Sciences (SSPS Inc,
version 19 for Windows) program was used. All tests
will be two-tailed; a p value of <0.05 was considered
significant. Results will be expressed as mean (standard
deviation) or median interquartile range unless other-
wise stated.
Results
A total of 191 immunocompromised patients were
included in the present study. Patient demographics are
shown in Table 1. The mean age of the patient cohort
was 50.5 years. The most common causes of immunosup-
pression were hematological malignancies (129 patients,
68%), particularly acute myeloid leukemia (56 patients,
29%) and malignant lymphoma (20 patients, 11%). Median
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Table 1 Demographics of 191 immunosuppressed patients undergoing BAL for suspicion of Invasive fungal disease,
classified according to the EORTC/NIAID
Patient characteristics All Possible Probable Proven No
Patient number (%) 191(100) 42(22) 8(4.2) 3(1.6) 138(72.3)
Age, yr 50.5(19–80) 44(22–80) 49.5(24–60) 42.67(29–70) 52.4(19–79)
Male gender (%) 116(60.7) 28(66.7) 4(50) 3(100) 81(58.7)
Symptoms
Fever (%) 95(49.7) 29(69) 3(37) 1(33.3) 62(44.9)
Cough (%) 97(50.8) 22(52.4) 4(50) 1(33.3) 70(50.7)
Dyspnea (%) 75(39.3) 15(35.7) 4(50) 0 56(40.6)
Sputum (%) 40(20.9) 10(23.8) 0 0 30(21.7)
Chills (%) 17(8.9) 1(2.4) 2(25) 0 14(10.1)
Chest radiograph/CT scan
Infiltrates (%) 105(55) 24(57.1) 6(75) 2(66.7) 73(52.9)
Suspicion of fungi lesion (%) 53(27.7) 17(40.5) 4(50) 3(100) 29(21)
Stem cell transplantation
Allogen (%) 48(25.1) 11(26.2) 4(100) 3(100) 30(21.7)
Autolog (%) 12(6.3) 6(14.3) 0 0 6(4.3)
Immunosuppressive therapy
Steroids (%) 67(35.1) 13(31) 2(25) 0 52(37.7)
Ciclosporine (%) 48(25.1) 13(31) 4(50) 1(33.3) 30(21.7)
Mycophenolate (%) 28(14.7) 4(9.5) 0 0 24(17.4)
Azathioprine (%) 9(4.7) 2(4.8) 1(12.5) 0 6(5.3)
Sirolimus (%) 10(5.2) 2(4.8) 1(12.5) 0 7(5.1)
Tacrolimus (%) 8(4.2) 0 0 0 8(5.8)
Antimicrobial therapy at bronchoscopy
Antibacterial (%) 163(85.3) 39(92.9) 8(100) 3(100) 113(81.3)
Antiviral (%) 66(34.6) 13(31) 3(37.5) 2(66.7) 48(34.8)
Antifungal (%) 111(58.1) 32(76.2) 7(87.5) 3(100) 69(50)
Disease
Hematologic disorders (%) 129(67.5) 33(78.6) 8(100) 3(100) 85(61.6)
Solid organ transplants (%) 26(13.6) 4(9.5) 0 0 22(15.9)
AIDS (%) 12(6.3) 0 0 0 12((8.7)
Autoimmune disorders (%) 24(12.6) 5(11.9) 0 0 19(13.8)
Microbiology
Aspergillus culture BAL (%) 8(4.2) 2(4.8) 2(25) 1(33.3) 3(2.2)
Bacteriology BAL (%) 28(14.7) 3(7.1) 1(12.5) 0 24(17.4)
Positive nPCR BAL (%) 55(28.8) 10(23.8) 4(50) 0 41(29.7)
Galactamannan in blood, ng/ml 0.226(0.1-3) 0.171(0.1-0.5) 0.488(0.1-1.3) 1.1(0.1-3) 0.178(0.1-1.3)
CRP (mg/L) 76.4(0–410) 84.8(0.9-296) 71.8(2.9-240) 61.6(6.8-116) 74(0–410)
Leukocytes (x103/L) 7.8 4.8 2.0 2.1 9.2
BAL cells (x106/L) 313.8 183.6 159.4 678.3 351.6
macrophages (in%) 69.1 71.0 82.4 60.5 68
lymphocytes (in%) 15.7 15.3 11.8 4.0 16.2
neutrophiles (in%) 16.4 9.4 6.7 35.5 18.5
eosinophiles (in%) 0.9 0.8 0.8 0.0 1
Abbreviations: BAL = Bronchoalveolar lavage.
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leukocyte counts and CRP were similar in all patient
groups (p = ns). Overall, 60 (31%) of the patients
underwent stem cell transplantation. Mean duration of
hospitalization before bronchoscopy was 11.1 (±18.6) days.
The vast majority of patients required bronchoscopy due
to fever and cough. Fifty-five percent presented infiltrates
in the chest-x-ray, where up only 28% where considered
to be suspected of IFD by the radiologists. A total of 85%
of the patients were on antibiotics, 58% on antifungal and
35% on antiviral therapy at the time of bronchoscopy.
In addition to bronchoalveolar lavage, 15 (7.9%) trans-
bronchial biopsies, 11 (5.8%) endobronchial biopsies and
3 (1.6%) TBNA from the parenchyma have been per-
formed during bronchoscopy. There were no major
complications of the procedure. Cytological analysis of
BAL revealed a mean of 313x106 cells, hereby 69%
macrophages, 16% neutrophiles, 16% lymphocytes, and
1% eosinophiles. There was no difference in the differen-
tial cell counts among patients with proven, probable
and possible IFD.
Histological confirmation of the diagnosis was achieved
in 35 patients. Eight (4.2%) patients were submitted to
open lung biopsy. Out of 37 deaths observed in the study,
a total of 24 autopsies were performed. In 2 cases with-
out autopsy, further tissue sections were previously
obtained for examination (transbronchial biopsy, open
lung biopsy, one case each). Thus, histology was available
in 57 (29.8%) cases and in 26 (70.3%) of the deceased
patients.
Diagnostic performance of conventional nested
Aspergillus PCR according to the EORTC/NIAID
classification
According to the EORTC/NIAID classification, “proven”,
“probable”, “possible” and “no” IFD was present in
3 (2%), 8 (4%), 42 (22%) and 138 (72%) of the cases,
respectively. Therefore, there were 53 patients with
potential IFD. Conventional nested PCR in the BAL was
positive in 55 cases (29%). From these, 0/3 (0%) in
proven, 4/8(50%) in probable, 10/42(24%) in possible
and 41/138(30%) in no IFD. Sensitivity, specificity, posi-
tive and negative predictive value of conventional nested
PCR according to the radiological and clinical suspicion
of IFD is presented in Table 2.
In 53 (28%) cases there was a strong clinical suspicion
of IFD in the chest-x-ray and/or chest-CT irrespective of
the EORTC/NIAID classification. However, from those,
only 15 (28%) had a positive conventional nested PCR.
Conventional nested PCR in the BAL was positive in
36/129 patients with hematologic disorders, 8/26 cases
of solid organ transplantation, 2/12 patients with AIDS
and 9/24 with autoimmune disorders. Thus, the under-
lying cause of immunsuppression did not significantly
influence PCR results in this study (p = 0.605) There
was no difference in PCR positivity among allogen (13/48),
autolog (5/12) and no (37/131) stem-cell transplant recipi-
ents either (p = 0.589).
A total of 111 (58%) of the patients were on anti-
fungal therapy at the time of bronchoscopy. Thereby,
anti-fungal therapy was administer to 10/11 (90.9%) of
the patients with proven or probable IFD and 32/42
(76.2%) patients with possible IFD, respectively. Results
of serum galactomannan were assessed in 105 patients
(55%). In 4 cases, galactomannan was considered posi-
tive (> 0.5 ng/ml). From those, 2 (50%) had a positive
PCR results. Galactomannan blood levels were similar
across all EORTC/NIAID groups (p = 0.123).
Discussion
In this study, we report the diagnostic performance of
conventional nested aspergillus PCR in the BAL fluid in
a well-characterized cohort of 191 immunosuppressed
patients. To our knowledge, this is the largest cohort of
IFD cases being prospectively analyzed by aspergillus
PCR in the BAL. Remarkably and in contrast to previous
data, our results fail to support the clinical applicability
of aspergillus PCR in the BAL in the immunosuppressed
population, mainly due to the lack of sensitivity and spe-
cificity of the method.
Our results are in contrast to some but not all previ-
ously published studies. While several authors [27-31]
suggested the sensitivity of aspergillus PCR in the BAL to
range between 80% and 100%, other authors described
much poorer results. For instance, Skladny et al. reports
a sensitivity of 43% for proven and 33% for probable IFD
using BAL PCR [19,32]. Remarkably, false negative
results in proven IFD have been described commonly.
Buchheidt et al. detected negative PCR results in the
BAL of two out of three patients with positive histo-
logical findings for invasive Aspergillosis [33] and Khot
et al. reported a negative PCR result from one patient
with a positive biopsy [18].
The low sensitivity of the assay in our study might
have several reasons. Firstly, we have additionally com-
puted the diagnostic performance of the assay by incorp-
orating the group of “possible” IFD as potentially having
IFD. As more cases not “formally” suffering from IFD
are included as diseased, there is a decrease in the pre-
test-probability, thus further reducing the sensitivity of
the test from 36% to 26%, as depicted in Table 2.
Secondly, previous studies selected patients by definite
radiographic findings or pneumonia, thus improving the
pre-test probability of the assay [18,29]. Thirdly, the
majority of our patient population (almost 60%) was on
chronic anti-fungal therapy at the time of bronchoscopy,
which might have decreased the number of organisms
present in the pulmonary parenchyma and consequently
in the BAL fluid, thus impairing identification by BAL
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PCR [34,35]. Importantly, data on previous fungal ther-
apy are missing in most previous reports [25,29,30,36].
As compared to older studies, it is plausible that recently
introduced, highly potent anti-fungal therapy such as
voriconazol and new prophylactic treatment schemata’s
reduce fungal load to undetectable amounts in the extra
vascular compartments. Fourthly, as only selected asper-
gillus primers have been applied, detection of other fun-
gal microorganisms was not possible using the current
assay. Although most IFD cases are related to aspergillus
infection, other fungi such as mucormycosis or rhizo-
phus with a similar or identical clinical presentation
would have been missed with the selected primers.
Fifthly, it is tempting to hypothesize that fungal microor-
ganisms are mainly present in the intravascular space,
thus precluding identification in the alveolar space. And
finally, we cannot exclude a technical failure of the
methods, although the consistency of the findings and
the broad experience of the investigators with molecular
techniques make this possibility unlikely [37-40].
In the current study, only 3 patients full field the cri-
teria of “proven” IFD according to the EORTC/NIAID
classification. Nevertheless, all presented a false-negative
result showing a negative PCR for Aspergillus in BAL. In
the first case, the patient had been on antifungal therapy
over 6 month at the time of bronchoscopy. Surprisingly,
with the exception of the positive histology obtained by
video-assisted thoracoscopic surgery, clinical EORTC/
NIAID classification was negative due to the absence of
neutropenia, fever, graft vs. host disease and current
steroid therapy, e.g. “no” IFD. In the second case, the pa-
tient was on cyclosporine, had a suspicion of fungal in-
fection due to the presence of a coin lesion on thoracic
CT-scan as well as a positive aspergillus culture in the
BAL, thus fulfilling the “probable” clinical criteria for
IFD. The third patient with a proven biopsy had a new
“fungi” suspect infiltrate in the CT scan, but low clinical
signs (“possible”) for IFD according to the EORTC/
NIAID classification. This exemplifies the low agreement
between the EORTC/NIAID classification, histological
findings and the clinical presentation in IFD. In all three
cases, the suspicion of fungal disease raised by the radi-
ologist lead to the initiation of antifungal medication.
While our results suggest an unexpected low sensitivity
of the aspergillus PCR in the BAL, the specificity of the
test is in line with previously reported data. Historical
controls have shown specificities ranging between 84%
and 100% [18,29,30]. This can be explained by the small
number of proven invasive aspergillosis.
Our study has a few limitations. The limited number
of “proven” and “probable” IFD cases hampers robust
inferences on the diagnostic performance of the any test
due the low prevalence of the disease (=low pre-test
probability). Moreover, the lack of a reliable diagnostic
gold-standard for IFD in the absence of histological sam-
ples and the heterogeneous clinical presentation of the
disease limit the diagnostic certainty in the majority of
cases. And finally, despite all efforts, we cannot defini-
tively exclude the possibility of a technical failure in the
assay procedure.
Conclusions
In summary, our results suggest a limited clinical applic-
ability of aspergillus PCR in the BAL for the detection of
invasive fungal disease (specifically invasive aspergillosis)
in a population of immunosuppressed patients.
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